July 17, 2019Open Access

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

Key Points

Key points are not available for this paper at this time.

Abstract

Despite the availability of newer active single agents, refractory patients were less likely to receive these therapies and continue to have inferior outcomes compared to those with relapsed disease. PTCL in the real world remains an unmet medical need, and improvements in front-line therapies are needed.

Bookmark

View Full Paper

Cite This Study

Lansigan et al. (Wed,) studied this question.

synapsesocial.com/papers/69d97e215e5bcb4e3b836d54 https://doi.org/https://doi.org/10.1159/000500666

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen2007 · 56 citations
2Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.2005 · 30 citations
3A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience2008 · 7 citations
4International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes2008 · 2,101 citations
5The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project2018 · 156 citations

Bookmark

View Full Paper